DDInter1042 DDInter82
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours. As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.[A203126, A203132] Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename
Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation. In depressed individuals, amoxapine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, &alpha;<sub>1</sub>-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression, and mixed symptoms of depression and anxiety or agitation.
Amoxapine {u} (Compound) resembles {v} (Compound) Chlordiazepoxide
Amoxapine {u} (Compound) resembles {v} (Compound) Lorazepam
Amoxapine {u} (Compound) binds {v} (Gene) HTR7
Amoxapine {u} (Compound) upregulates {v} (Gene) MSMO1
Amoxapine {u} (Compound) causes {v} (Side Effect) Flatulence
Amoxapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dronabinol
Amoxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Amoxapine {u} may lead to a major life threatening interaction when taken with {v} Anagrelide
Amoxapine (Compound) resembles Chlordiazepoxide (Compound)
Amoxapine (Compound) resembles Lorazepam (Compound)
Amoxapine (Compound) binds HTR7 (Gene)
Amoxapine (Compound) upregulates MSMO1 (Gene)
Amoxapine (Compound) causes Flatulence (Side Effect)
Amoxapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol
Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Amoxapine may lead to a major life threatening interaction when taken with Macimorelin
Amoxapine may lead to a major life threatening interaction when taken with Anagrelide